Status:
COMPLETED
Combined Hormone Therapy, C-reactive Protein(CRP) Levels and Life Quality in Natural Menopause Women
Lead Sponsor:
Karadeniz Technical University
Conditions:
CRP
Menopause
Eligibility:
FEMALE
45-55 years
Brief Summary
This study aims to assess the effect of low dose combined estradiol and norethindrone acetate hormone therapy on serum CRP levels and life quality in natural menopause women. 45 natural menopause wome...
Eligibility Criteria
Inclusion
- Accepting consent to participate in the research and signing the form;
- Postmenopausal women 45-55 years old
- not having had menstruation for the past 6 months;
- Hormone results compatible with menopause (FSH\> 20 milli-International unit(mIU) / mL, E2 \<20 mIU / mL) and presence of vasomotor and/or menopausal symptoms (moderate to severe);
- no systemic disease (Diabetes, hypertension, hyperlipidemia, ischemic heart disease), or no infectious disease in the past 2 weeks;
- not taking any hormone therapy or medication for at least 2 months;
- no contraindications for hormone therapy in routine menopause evaluation;
- Willingness to take hormone therapy
- No smoking.
Exclusion
- Any systemic disease (DM, HT, hyperlipidemia, ischemic heart disease) presence
- Smoking
- Contraindications for hormone therapy
- Failure to follow-up
- Inability to complete three months of hormone therapy
- Stopping hormone therapy due to vaginal bleeding during hormone therapy
Key Trial Info
Start Date :
August 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 30 2008
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT04424173
Start Date
August 1 2007
End Date
August 30 2008
Last Update
June 29 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.